Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 192

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Progress and problems with the use of suicide genes for targeted cancer therapy

Open access
Karjoo, Zahra, Chen, Xuguang, Hatefi, Arash·2016·Advanced Drug Delivery Reviews

Abstract

Among various gene therapy methods for cancer, suicide gene therapy attracts a special attention because it allows selective conversion of non-toxic compounds into cytotoxic drugs inside cancer cells. As a result, therapeutic index can be increased significantly by introducing high concentrations of cytotoxic molecules to the tumor environment while minimizing impact on normal tissues. Despite significant success at the preclinical level, no cancer suicide gene therapy protocol has delivered the desirable clinical significance yet. This review gives a critical look at the six main enzyme/prodrug systems that are used in suicide gene therapy of cancer and familiarizes readers with the state-of-the-art research and practices in this field. For each enzyme/prodrug system, the mechanisms of action, protein engineering strategies to enhance enzyme stability/affinity and chemical modification techniques to increase prodrug kinetics and potency are discussed. In each category, major clinical trials that have been performed in the past decade with each enzyme/prodrug system are discussed to highlight the progress to date. Finally, shortcomings are underlined and areas that need improvement in order to produce clinical significance are delineated.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.addr.2015.05.009

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Research works printed but not linked: 171

  1. Baban, 1998, Control of tumour vascular permeability, Adv. Drug Deliv. Rev., 34, 109, 10.1016/S0169-409X(98)00003-9 · DOI · Paper page
  2. Kobayashi, 2013, Improving conventional enhanced permeability and retention (EPR) effects; what is the appropriate target?, Theranostics, 4, 81, 10.7150/thno.7193 · DOI · Paper page
  3. DeVita, 2008, A history of cancer chemotherapy, Cancer Res., 68, 8643, 10.1158/0008-5472.CAN-07-6611 · DOI · Paper page
  4. Vandyke, 2010, Dysregulation of bone remodeling by imatinib mesylate, Blood, 115, 766, 10.1182/blood-2009-08-237404 · DOI
  5. Zhou, 2013, Biological rationale for the design of polymeric anti-cancer nanomedicines, J. Drug Target., 21, 1, 10.3109/1061186X.2012.723213 · DOI
  6. Yao, 2012, Optimization and internalization mechanisms of PEGylated adenovirus vector with targeting peptide for cancer gene therapy, Biomacromolecules, 13, 2402, 10.1021/bm300665u · doi:10.1021/bm300665u
  7. Yao, 2009, Systemic administration of a PEGylated adenovirus vector with a cancer-specific promoter is effective in a mouse model of metastasis, Gene Ther., 16, 1395, 10.1038/gt.2009.95 · DOI
  8. Shah, 2013, Targeted nanomedicine for suppression of CD44 and simultaneous cell death induction in ovarian cancer: an optimal delivery of siRNA and anticancer drug, Clin. Cancer Res., 19, 6193, 10.1158/1078-0432.CCR-13-1536 · DOI · Paper page
  9. Liu, 2015, Tumor suppressor p53 and its mutants in cancer metabolism, Cancer Lett., 356, 197, 10.1016/j.canlet.2013.12.025 · DOI · Paper page
  10. Senzer, 2013, Phase I study of a systemically delivered p53 nanoparticle in advanced solid tumors, Mol. Ther., 21, 1096, 10.1038/mt.2013.32 · DOI · Paper page
  11. Tabernero, 2013, First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement, Cancer Discov., 3, 406, 10.1158/2159-8290.CD-12-0429 · DOI · Paper page
  12. Chen, 2015, In vivo delivery of miRNAs for cancer therapy: challenges and strategies, Adv. Drug Deliv. Rev., 81, 128, 10.1016/j.addr.2014.05.009 · DOI · Paper page
  13. van der Meel, 2013, Ligand-targeted particulate nanomedicines undergoing clinical evaluation: current status, Adv. Drug Deliv. Rev., 65, 1284, 10.1016/j.addr.2013.08.012 · DOI · Paper page
  14. Portsmouth, 2007, Suicide genes for cancer therapy, Mol. Asp. Med., 28, 4, 10.1016/j.mam.2006.12.001 · DOI
  15. Dorer, 2009, Targeting cancer by transcriptional control in cancer gene therapy and viral oncolysis, Adv. Drug Deliv. Rev., 61, 554, 10.1016/j.addr.2009.03.013 · DOI
  16. Yao, 2011, Current targeting strategies for adenovirus vectors in cancer gene therapy, Curr. Cancer Drug Targets, 11, 810, 10.2174/156800911796798896 · doi:10.2174/156800911796798896
  17. Xu, 2011, Gene therapy with tumor-specific promoter mediated suicide gene plus IL-12 gene enhanced tumor inhibition and prolonged host survival in a murine model of Lewis lung carcinoma, J. Transl. Med., 9, 39, 10.1186/1479-5876-9-39 · DOI
  18. Dabrowska, 2004, CEA-negative glioblastoma and melanoma cells are sensitive to cytosine deaminase/5-fluorocytosine therapy directed by the carcinoembryonic antigen promoter, Acta Biochim. Pol., 51, 723, 10.18388/abp.2004_3557 · doi:10.18388/abp.2004_3557
  19. Greco, 2003, How to overcome (and exploit) tumor hypoxia for targeted gene therapy, J. Cell. Physiol., 197, 312, 10.1002/jcp.10374 · DOI
  20. Scott, 2004, Radiation and hypoxia inducible gene therapy systems, Cancer Metastasis Rev., 23, 269, 10.1023/B:CANC.0000031766.58614.f1 · doi:10.1023/b:canc.0000031766.58614.f1
  21. Robson, 2003, Transcriptional targeting in cancer gene therapy, J. Biomed. Biotechnol., 2003, 110
  22. Papadakis, 2004, Promoters and control elements: designing expression cassettes for gene therapy, Curr. Gene Ther., 4, 89, 10.2174/1566523044578077 · DOI · Paper page
  23. Nemunaitis, 2010, A phase I study of telomerase-specific replication competent oncolytic adenovirus (telomelysin) for various solid tumors, Mol. Ther., 18, 429, 10.1038/mt.2009.262 · DOI · Paper page
  24. Wu, 2001, Chimeric PSA enhancers exhibit augmented activity in prostate cancer gene therapy vectors, Gene Ther., 8, 1416, 10.1038/sj.gt.3301549 · DOI
  25. Kanegae, 2011, High-level expression by tissue/cancer-specific promoter with strict specificity using a single-adenoviral vector, Nucleic Acids Res., 39, e7, 10.1093/nar/gkq966 · DOI
  26. Chen, 2015, The potential of the human osteopontin promoter and single-nucleotide polymorphisms for targeted cancer gene therapy, Curr. Gene Ther., 15, 82, 10.2174/1566523214666141127094033 · doi:10.2174/1566523214666141127094033
  27. Chuah, 2014, Liver-specific transcriptional modules identified by genome-wide in silico analysis enable efficient gene therapy in mice and non-human primates, Mol. Ther., 22, 1605, 10.1038/mt.2014.114 · DOI
  28. Huber, 1994, Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase, Proc. Natl. Acad. Sci. U. S. A., 91, 8302, 10.1073/pnas.91.17.8302 · DOI · Paper page
  29. Ardiani, 2012, Enzymes to die for: exploiting nucleotide metabolizing enzymes for cancer gene therapy, Curr. Gene Ther., 12, 77, 10.2174/156652312800099571 · DOI
  30. Xiao, 2013, Tanshinone IIA increases the bystander effect of herpes simplex virus thymidine kinase/ganciclovir gene therapy via enhanced gap junctional intercellular communication, PLoS One, 8, e67662, 10.1371/journal.pone.0067662 · doi:10.1371/journal.pone.0067662
  31. Freeman, 1993, The “bystander effect”: tumor regression when a fraction of the tumor mass is genetically modified, Cancer Res., 53, 5274
  32. Engelmann, 2002, Importance, mechanisms and limitations of the distant bystander effect in cancer gene therapy of experimental liver tumors, Cancer Lett., 179, 59, 10.1016/S0304-3835(01)00854-0 · doi:10.1016/s0304-3835(01)00854-0
  33. Kuriyama, 2004, Immune response to suicide gene therapy, Methods Mol. Med., 90, 353
  34. Pierrefite-Carle, 2002, Subcutaneous or intrahepatic injection of suicide gene modified tumour cells induces a systemic antitumour response in a metastatic model of colon carcinoma in rats, Gut, 50, 387, 10.1136/gut.50.3.387 · doi:10.1136/gut.50.3.387
  35. Aguilar, 2011, Cytotoxic immunotherapy strategies for cancer: mechanisms and clinical development, J. Cell. Biochem., 112, 1969, 10.1002/jcb.23126 · DOI
  36. Agard, 2001, Immune-dependent distant bystander effect after adenovirus-mediated suicide gene transfer in a rat model of liver colorectal metastasis, Cancer Gene Ther., 8, 128, 10.1038/sj.cgt.7700281 · doi:10.1038/sj.cgt.7700281
  37. Niculescu-Duvaz, 2005, Introduction to the background, principles, and state of the art in suicide gene therapy, Mol. Biotechnol., 30, 71, 10.1385/MB:30:1:071 · DOI
  38. Yoon, 2005, Development of prodrugs for enzyme-mediated, tumor-selective therapy, Curr. Med. Chem. Anticancer Agents, 5, 107, 10.2174/1568011053174837 · doi:10.2174/1568011053174837
  39. Niculescu-Duvaz, 2004, Design of prodrugs for suicide gene therapy, Methods Mol. Med., 90, 161
  40. Niculescu-Duvaz, 1999, Self-immolative anthracycline prodrugs for suicide gene therapy, J. Med. Chem., 42, 2485, 10.1021/jm980696v · doi:10.1021/jm980696v
  41. Tranoy-Opalinski, 2014, Beta-glucuronidase-responsive prodrugs for selective cancer chemotherapy: An update, Eur. J. Med. Chem., 74, 302, 10.1016/j.ejmech.2013.12.045 · DOI
  42. Tranoy-Opalinski, 2008, Design of self-immolative linkers for tumour-activated prodrug therapy, Anti Cancer Agents Med. Chem., 8, 618, 10.2174/187152008785133065 · DOI
  43. Lammers, 2012, Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress, J. Control. Release, 161, 175, 10.1016/j.jconrel.2011.09.063 · DOI · Paper page
  44. Halama, 2009, Polymer-based non-viral gene delivery as a concept for the treatment of cancer, Pharmacol. Rep., 61, 993, 10.1016/S1734-1140(09)70160-4 · DOI
  45. McCarthy, 2010, Advances with the use of bio-inspired vectors towards creation of artificial viruses, Expert Opin. Drug Deliv., 7, 497, 10.1517/17425240903579989 · DOI
  46. Mohit, 2013, Biological delivery approaches for gene therapy: strategies to potentiate efficacy and enhance specificity, Mol. Immunol., 56, 599, 10.1016/j.molimm.2013.06.005 · DOI
  47. Ginn, 2013, Gene therapy clinical trials worldwide to 2012 — an update, J. Gene Med., 15, 65, 10.1002/jgm.2698 · DOI · Paper page
  48. Beatty, 2012, Chapter two — adenovirus strategies for tissue-specific targeting, Adv. Cancer Res., 115, 39, 10.1016/B978-0-12-398342-8.00002-1 · DOI
  49. Shen, 2006, Herpes simplex virus 1 (HSV-1) for cancer treatment, Cancer Gene Ther., 13, 975, 10.1038/sj.cgt.7700946 · DOI · Paper page
  50. Thomas, 2003, Progress and problems with the use of viral vectors for gene therapy, Nat. Rev. Genet., 4, 346, 10.1038/nrg1066 · DOI · Paper page
  51. Penet, 2012, Prodrug enzymes and their applications in image-guided therapy of cancer: tracking prodrug enzymes to minimize collateral damage, J. Gene Med., 2, 22
  52. Wilcox, 1992, Replication, latent infection, and reactivation in neuronal culture with a herpes simplex virus thymidine kinase-negative mutant, Virology, 187, 348, 10.1016/0042-6822(92)90326-K · doi:10.1016/0042-6822(92)90326-k
  53. Chen, 2004, Failure of thymidine kinase-negative herpes simplex virus to reactivate from latency following efficient establishment, J. Virol., 78, 520, 10.1128/JVI.78.1.520-523.2004 · doi:10.1128/jvi.78.1.520-523.2004
  54. Piret, 2011, Resistance of herpes simplex viruses to nucleoside analogues: mechanisms, prevalence, and management, Antimicrob. Agents Chemother., 55, 459, 10.1128/AAC.00615-10 · DOI · Paper page
  55. Gallois-Montbrun, 2004, Antiviral nucleoside analogs phosphorylation by nucleoside diphosphate kinase, Mini Rev. Med. Chem., 4, 361, 10.2174/1389557043403990 · doi:10.2174/1389557043403990
  56. Beltinger, 1999, Herpes simplex virus thymidine kinase/ganciclovir-induced apoptosis involves ligand-independent death receptor aggregation and activation of caspases, Proc. Natl. Acad. Sci. U. S. A., 96, 8699, 10.1073/pnas.96.15.8699 · DOI · Paper page
  57. Nicholas, 2003, Suicide gene therapy with Herpes simplex virus thymidine kinase and ganciclovir is enhanced with connexins to improve gap junctions and bystander effects, Histol. Histopathol., 18, 495
  58. Preuss, 2011, Cancer suicide gene therapy with TK.007: superior killing efficiency and bystander effect, J. Mol. Med., 89, 1113, 10.1007/s00109-011-0777-8 · DOI
  59. Mesnil, 2000, Bystander effect in herpes simplex virus-thymidine kinase/ganciclovir cancer gene therapy: role of gap-junctional intercellular communication, Cancer Res., 60, 3989
  60. Dachs, 2009, Bystander or no bystander for gene directed enzyme prodrug therapy, Molecules, 14, 4517, 10.3390/molecules14114517 · DOI
  61. Black, 2001, Herpes simplex virus-1 thymidine kinase mutants created by semi-random sequence mutagenesis improve prodrug-mediated tumor cell killing, Cancer Res., 61, 3022
  62. Ardiani, 2010, Fusion enzymes containing HSV-1 thymidine kinase mutants and guanylate kinase enhance prodrug sensitivity in vitro and in vivo, Cancer Gene Ther., 17, 86, 10.1038/cgt.2009.60 · doi:10.1038/cgt.2009.60
  63. Balzarini, 2006, Engineering of a single conserved amino acid residue of herpes simplex virus type 1 thymidine kinase allows a predominant shift from pyrimidine to purine nucleoside phosphorylation, J. Biol. Chem., 281, 19273, 10.1074/jbc.M600414200 · doi:10.1074/jbc.m600414200
  64. Blumenthal, 2007, Effective suicide gene therapy for leukemia in a model of insertional oncogenesis in mice, Mol. Ther., 15, 183, 10.1038/sj.mt.6300015 · doi:10.1038/sj.mt.6300015
  65. Barzon, 2009, HSV-TK/IL-2 gene therapy for glioblastoma multiforme, Methods Mol. Biol., 542, 529, 10.1007/978-1-59745-561-9_28 · doi:10.1007/978-1-59745-561-9_28
  66. Pan, 2012, The adeno-associated virus-mediated HSV-TK/GCV suicide system: a potential strategy for the treatment of bladder carcinoma, Med. Oncol., 29, 1938, 10.1007/s12032-011-0091-x · doi:10.1007/s12032-011-0091-x
  67. Wang, 2011, HSV-TK/GCV cancer suicide gene therapy by a designed recombinant multifunctional vector, Nanomedicine, 7, 193, 10.1016/j.nano.2010.08.003 · doi:10.1016/j.nano.2010.08.003
  68. Voges, 2003, Imaging-guided convection-enhanced delivery and gene therapy of glioblastoma, Ann. Neurol., 54, 479, 10.1002/ana.10688 · DOI · Paper page
  69. Nasu, 2007, Suicide gene therapy with adenoviral delivery of HSV-tK gene for patients with local recurrence of prostate cancer after hormonal therapy, Mol. Ther., 15, 834, 10.1038/sj.mt.6300096 · doi:10.1038/sj.mt.6300096
  70. Li, 2007, Adjuvant adenovirus-mediated delivery of herpes simplex virus thymidine kinase administration improves outcome of liver transplantation in patients with advanced hepatocellular carcinoma, Clin. Cancer Res., 13, 5847, 10.1158/1078-0432.CCR-07-0499 · DOI
  71. Xu, 2009, Phase I and biodistribution study of recombinant adenovirus vector-mediated herpes simplex virus thymidine kinase gene and ganciclovir administration in patients with head and neck cancer and other malignant tumors, Cancer Gene Ther., 16, 723, 10.1038/cgt.2009.19 · DOI
  72. Sangro, 2010, A phase I clinical trial of thymidine kinase-based gene therapy in advanced hepatocellular carcinoma, Cancer Gene Ther., 17, 837, 10.1038/cgt.2010.40 · doi:10.1038/cgt.2010.40
  73. Langford, 2009, A preclinical assessment of the safety and biodistribution of an adenoviral vector containing the herpes simplex virus thymidine kinase gene (Cerepro) after intracerebral administration, J. Gene Med., 11, 468, 10.1002/jgm.1328 · doi:10.1002/jgm.1328
  74. van Putten, 2010, Sitimagene ceradenovec: a gene-based drug for the treatment of operable high-grade glioma, Future Oncol., 6, 1691, 10.2217/fon.10.134 · DOI
  75. Matthews, 2009, Identifying the safety profile of Ad5.SSTR/TK.RGD, a novel infectivity-enhanced bicistronic adenovirus, in anticipation of a phase I clinical trial in patients with recurrent ovarian cancer, Clin. Cancer Res., 15, 4131, 10.1158/1078-0432.CCR-08-3354 · DOI
  76. Witlox, 2002, Epidermal growth factor receptor targeting enhances adenoviral vector based suicide gene therapy of osteosarcoma, J. Gene Med., 4, 510, 10.1002/jgm.308 · doi:10.1002/jgm.308
  77. Nicklin, 2002, Tropism-modified adenoviral and adeno-associated viral vectors for gene therapy, Curr. Gene Ther., 2, 273, 10.2174/1566523023347797 · DOI
  78. Verheije, 2012, Retargeting of viruses to generate oncolytic agents, Adv. Virol., 2012, 798526, 10.1155/2012/798526 · DOI
  79. Kim, 2012, A phase I clinical trial of Ad5.SSTR/TK.RGD, a novel infectivity-enhanced bicistronic adenovirus, in patients with recurrent gynecologic cancer, Clin. Cancer Res., 18, 3440, 10.1158/1078-0432.CCR-11-2852 · DOI
  80. Kubo, 2003, Phase I dose escalation clinical trial of adenovirus vector carrying osteocalcin promoter-driven herpes simplex virus thymidine kinase in localized and metastatic hormone-refractory prostate cancer, Hum. Gene Ther., 14, 227, 10.1089/10430340360535788 · doi:10.1089/10430340360535788
  81. Papanastasopoulos, 2014, Molecular basis of 5-fluorouracil-related toxicity: lessons from clinical practice, Anticancer Res., 34, 1531
  82. Miller, 2002, Intratumoral 5-fluorouracil produced by cytosine deaminase/5-fluorocytosine gene therapy is effective for experimental human glioblastomas, Cancer Res., 62, 773
  83. Kuriyama, 1998, Bystander effect caused by cytosine deaminase gene and 5-fluorocytosine in vitro is substantially mediated by generated 5-fluorouracil, Anticancer Res., 18, 3399
  84. Garcia-Sanchez, 1998, Cytosine deaminase adenoviral vector and 5-fluorocytosine selectively reduce breast cancer cells 1 million-fold when they contaminate hematopoietic cells: a potential purging method for autologous transplantation, Blood, 92, 672, 10.1182/blood.V92.2.672 · doi:10.1182/blood.v92.2.672
  85. Ostertag, 2012, Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector, J. Neuro Oncol., 14, 145, 10.1093/neuonc/nor199 · DOI
  86. Kaliberov, 2012, Chapter seven — cancer treatment with gene therapy and radiation therapy, Adv. Cancer Res., 115, 221, 10.1016/B978-0-12-398342-8.00007-0 · DOI
  87. Tong, 2011, Imaging beyond the diagnosis: image-guided enzyme/prodrug cancer therapy, Acta Biochim. Biophys. Sin., 43, 4, 10.1093/abbs/gmq113 · DOI
  88. Haack, 2000, Induction of protective immunity against syngeneic rat cancer cells by expression of the cytosine deaminase suicide gene, Cancer Gene Ther., 7, 1357, 10.1038/sj.cgt.7700245 · doi:10.1038/sj.cgt.7700245
  89. Kaliberova, 2008, Molecular chemotherapy of pancreatic cancer using novel mutant bacterial cytosine deaminase gene, Mol. Cancer Ther., 7, 2845, 10.1158/1535-7163.MCT-08-0347 · doi:10.1158/1535-7163.mct-08-0347
  90. Deng, 2011, Antitumor activity of mutant bacterial cytosine deaminase gene for colon cancer, World J. Gastroenterol., 17, 2958, 10.3748/wjg.v17.i24.2958 · DOI
  91. Fuchita, 2009, Bacterial cytosine deaminase mutants created by molecular engineering show improved 5-fluorocytosine-mediated cell killing in vitro and in vivo, Cancer Res., 69, 4791, 10.1158/0008-5472.CAN-09-0615 · DOI
  92. Stolworthy, 2008, Yeast cytosine deaminase mutants with increased thermostability impart sensitivity to 5-fluorocytosine, J. Mol. Biol., 377, 854, 10.1016/j.jmb.2008.01.002 · DOI
  93. Korkegian, 2005, Computational thermostabilization of an enzyme, Science, 308, 857, 10.1126/science.1107387 · DOI · Paper page
  94. Shi, 2009, Pharmacokinetics and the bystander effect in CD::UPRT/5-FC bi-gene therapy of glioma, Chin. Med. J., 122, 1267
  95. Richard, 2007, Sensitivity of 5-fluorouracil-resistant cancer cells to adenovirus suicide gene therapy, Cancer Gene Ther., 14, 57, 10.1038/sj.cgt.7700980 · doi:10.1038/sj.cgt.7700980
  96. Freytag, 2002, Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer, Cancer Res., 62, 4968
  97. Freytag, 2007, Replication-competent adenovirus-mediated suicide gene therapy with radiation in a preclinical model of pancreatic cancer, Mol. Ther., 15, 1600, 10.1038/sj.mt.6300212 · doi:10.1038/sj.mt.6300212
  98. Freytag, 2003, Phase I study of replication-competent adenovirus-mediated double-suicide gene therapy in combination with conventional-dose three-dimensional conformal radiation therapy for the treatment of newly diagnosed, intermediate- to high-risk prostate cancer, Cancer Res., 63, 7497
  99. Freytag, 2007, Phase I trial of replication-competent adenovirus-mediated suicide gene therapy combined with IMRT for prostate cancer, Mol. Ther., 15, 1016, 10.1038/mt.sj.6300120 · doi:10.1038/mt.sj.6300120
  100. Freytag, 2007, Five-year follow-up of trial of replication-competent adenovirus-mediated suicide gene therapy for treatment of prostate cancer, Mol. Ther., 15, 636, 10.1038/sj.mt.6300068 · DOI
  101. Perez, 2012, Design and selection of Toca 511 for clinical use: modified retroviral replicating vector with improved stability and gene expression, Mol. Ther., 20, 1689, 10.1038/mt.2012.83 · DOI
  102. Stedt, 2013, Improved therapeutic effect on malignant glioma with adenoviral suicide gene therapy combined with temozolomide, Gene Ther., 20, 1165, 10.1038/gt.2013.46 · DOI
  103. Greco, 2001, Gene directed enzyme/prodrug therapy of cancer: historical appraisal and future prospectives, J. Cell. Physiol., 187, 22, 10.1002/1097-4652(2001)9999:9999<::AID-JCP1060>3.0.CO;2-H · DOI · Paper page
  104. Green, 2013, The flavin reductase MsuE is a novel nitroreductase that can efficiently activate two promising next-generation prodrugs for gene-directed enzyme prodrug therapy, Cancers (Basel), 5, 985, 10.3390/cancers5030985 · doi:10.3390/cancers5030985
  105. Chung-Faye, 2001, Virus-directed, enzyme prodrug therapy with nitroimidazole reductase: a phase I and pharmacokinetic study of its prodrug, CB1954, Clin. Cancer Res., 7, 2662
  106. Prosser, 2010, Discovery and evaluation of Escherichia coli nitroreductases that activate the anti-cancer prodrug CB1954, Biochem. Pharmacol., 79, 678, 10.1016/j.bcp.2009.10.008 · doi:10.1016/j.bcp.2009.10.008
  107. Grohmann, 2009, A mammalianized synthetic nitroreductase gene for high-level expression, BMC Cancer, 9, 301, 10.1186/1471-2407-9-301 · DOI
  108. Prosser, 2013, Creation and screening of a multi-family bacterial oxidoreductase library to discover novel nitroreductases that efficiently activate the bioreductive prodrugs CB1954 and PR-104A, Biochem. Pharmacol., 85, 1091, 10.1016/j.bcp.2013.01.029 · DOI
  109. Swe, 2012, Targeted mutagenesis of the Vibrio fischeri flavin reductase FRase I to improve activation of the anticancer prodrug CB1954, Biochem. Pharmacol., 84, 775, 10.1016/j.bcp.2012.07.002 · DOI
  110. Green, 2013, Pseudomonas aeruginosa NfsB and nitro-CBI-DEI — a promising enzyme/prodrug combination for gene directed enzyme prodrug therapy, Mol. Cancer, 12, 58, 10.1186/1476-4598-12-58 · doi:10.1186/1476-4598-12-58
  111. Patel, 2009, A phase I/II clinical trial in localized prostate cancer of an adenovirus expressing nitroreductase with CB1954 [correction of CB1984], Mol. Ther., 17, 1292, 10.1038/mt.2009.80 · DOI
  112. Barar, 2012, Translational approaches towards cancer gene therapy: hurdles and hopes, Biogeosciences, 2, 127
  113. Nouri, 2015, Genetically engineered theranostic mesenchymal stem cells for the evaluation of the anticancer efficacy of enzyme/prodrug systems, J. Control. Release, 200, 179, 10.1016/j.jconrel.2015.01.003 · DOI
  114. Guise, 2010, The bioreductive prodrug PR-104A is activated under aerobic conditions by human aldo-keto reductase 1C3, Cancer Res., 70, 1573, 10.1158/0008-5472.CAN-09-3237 · DOI · Paper page
  115. Hedley, 2007, Carboxypeptidase-G2-based gene-directed enzyme-prodrug therapy: a new weapon in the GDEPT armoury, Nat. Rev. Cancer, 7, 870, 10.1038/nrc2247 · DOI
  116. Palmer, 2004, Virus-directed enzyme prodrug therapy: intratumoral administration of a replication-deficient adenovirus encoding nitroreductase to patients with resectable liver cancer, J. Clin. Oncol., 22, 1546, 10.1200/JCO.2004.10.005 · doi:10.1200/jco.2004.10.005
  117. Stribbling, 2000, Regressions of established breast carcinoma xenografts by carboxypeptidase G2 suicide gene therapy and the prodrug CMDA are due to a bystander effect, Hum. Gene Ther., 11, 285, 10.1089/10430340050016021 · doi:10.1089/10430340050016021
  118. Francis, 2002, A phase I trial of antibody directed enzyme prodrug therapy (ADEPT) in patients with advanced colorectal carcinoma or other CEA producing tumours, Br. J. Cancer, 87, 600, 10.1038/sj.bjc.6600517 · DOI · Paper page
  119. Friedlos, 2002, Three new prodrugs for suicide gene therapy using carboxypeptidase G2 elicit bystander efficacy in two xenograft models, Cancer Res., 62, 1724
  120. Mancini, 2009, A novel technique to monitor carboxypeptidase G2 expression in suicide gene therapy using 19F magnetic resonance spectroscopy, NMR Biomed., 22, 561, 10.1002/nbm.1375 · doi:10.1002/nbm.1375
  121. Mahato, 2011, Prodrugs for improving tumor targetability and efficiency, Adv. Drug Deliv. Rev., 63, 659, 10.1016/j.addr.2011.02.002 · DOI · Paper page
  122. Martin, 1997, Antibody-directed enzyme prodrug therapy: pharmacokinetics and plasma levels of prodrug and drug in a phase I clinical trial, Cancer Chemother. Pharmacol., 40, 189, 10.1007/s002800050646 · DOI
  123. Chiocca, 2004, Cytochrome p450-based gene therapies for cancer, Methods Mol. Med., 90, 203
  124. Huang, 2001, Modulation of cyclophosphamide-based cytochrome P450 gene therapy using liver P450 inhibitors, Cancer Gene Ther., 8, 450, 10.1038/sj.cgt.7700325 · DOI
  125. Chen, 2002, Cytochrome P450 gene-directed enzyme prodrug therapy (GDEPT) for cancer, Curr. Pharm. Des., 8, 1405, 10.2174/1381612023394566 · doi:10.2174/1381612023394566
  126. Salmons, 2003, Treatment of inoperable pancreatic carcinoma using a cell-based local chemotherapy: results of a phase I/II clinical trial, J. Gastroenterol., 38, 78
  127. Braybrooke, 2005, Phase I study of MetXia-P450 gene therapy and oral cyclophosphamide for patients with advanced breast cancer or melanoma, Clin. Cancer Res., 11, 1512, 10.1158/1078-0432.CCR-04-0155 · doi:10.1158/1078-0432.ccr-04-0155
  128. Touati, 2014, A suicide gene therapy combining the improvement of cyclophosphamide tumor cytotoxicity and the development of an anti-tumor immune response, Curr. Gene Ther., 14, 236, 10.2174/1566523214666140424152734 · DOI
  129. Gadi, 2003, A long-acting suicide gene toxin, 6-methylpurine, inhibits slow growing tumors after a single administration, J. Pharmacol. Exp. Ther., 304, 1280, 10.1124/jpet.102.044743 · doi:10.1124/jpet.102.044743
  130. Hong, 2004, Excellent in vivo bystander activity of fludarabine phosphate against human glioma xenografts that express the Escherichia coli purine nucleoside phosphorylase gene, Cancer Res., 64, 6610, 10.1158/0008-5472.CAN-04-0012 · DOI
  131. Martiniello-Wilks, 1998, In vivo gene therapy for prostate cancer: preclinical evaluation of two different enzyme-directed prodrug therapy systems delivered by identical adenovirus vectors, Hum. Gene Ther., 9, 1617, 10.1089/hum.1998.9.11-1617 · doi:10.1089/hum.1998.9.11-1617
  132. Lockett, 1997, Relative efficiency of tumor cell killing in vitro by two enzyme-prodrug systems delivered by identical adenovirus vectors, Clin. Cancer Res., 3, 2075
  133. Afshar, 2009, Humanized ADEPT comprised of an engineered human purine nucleoside phosphorylase and a tumor targeting peptide for treatment of cancer, Mol. Cancer Ther., 8, 185, 10.1158/1535-7163.MCT-08-0652 · doi:10.1158/1535-7163.mct-08-0652
  134. Voeks, 2002, Gene therapy for prostate cancer delivered by ovine adenovirus and mediated by purine nucleoside phosphorylase and fludarabine in mouse models, Gene Ther., 9, 759, 10.1038/sj.gt.3301698 · DOI
  135. Parker, 2011, Effect of expression of adenine phosphoribosyltransferase on the in vivo anti-tumor activity of prodrugs activated by E. coli purine nucleoside phosphorylase, Cancer Gene Ther., 18, 390, 10.1038/cgt.2011.4 · doi:10.1038/cgt.2011.4
  136. Bennett, 2003, Designer gene therapy using an Escherichia coli purine nucleoside phosphorylase/prodrug system, Chem. Biol., 10, 1173, 10.1016/j.chembiol.2003.11.008 · doi:10.1016/j.chembiol.2003.11.008
  137. Parker, 2005, Design and evaluation of 5′-modified nucleoside analogs as prodrugs for an E. coli purine nucleoside phosphorylase mutant, Nucleosides Nucleotides Nucleic Acids, 24, 387, 10.1081/NCN-200059807 · doi:10.1081/ncn-200059807
  138. Xie, 2011, Targeted expression of Escherichia coli purine nucleoside phosphorylase and Fludara(R) for prostate cancer therapy, J. Gene Med., 13, 680, 10.1002/jgm.1620 · doi:10.1002/jgm.1620
  139. Chen, 2013, Dual specific antitumor effects of Semliki Forest virus-based DNA vector carrying suicide Escherichia coli purine nucleoside phosphorylase gene via Salmonella, Int. J. Oncol., 42, 2009, 10.3892/ijo.2013.1900 · doi:10.3892/ijo.2013.1900
  140. Sorscher, 2012, In vivo antitumor activity of intratumoral fludarabine phosphate in refractory tumors expressing E. coli purine nucleoside phosphorylase, Cancer Chemother. Pharmacol., 70, 321, 10.1007/s00280-012-1908-9 · DOI
  141. Greco, 2001, Horseradish peroxidase-mediated gene therapy: choice of prodrugs in oxic and anoxic tumor conditions, Mol. Cancer Ther., 1, 151
  142. Greco, 2002, Oxic and anoxic enhancement of radiation-mediated toxicity by horseradish peroxidase/indole-3-acetic acid gene therapy, Int. J. Radiat. Biol., 78, 173, 10.1080/09553000110097983 · DOI
  143. Pommier, 2006, Topoisomerase I inhibitors: camptothecins and beyond, Nat. Rev. Cancer, 6, 789, 10.1038/nrc1977 · DOI · Paper page
  144. Metz, 2013, Neural stem cell-mediated delivery of irinotecan-activating carboxylesterases to glioma: implications for clinical use, Stem cells Transl. Med., 2, 983, 10.5966/sctm.2012-0177 · DOI
  145. Mathijssen, 2001, Clinical pharmacokinetics and metabolism of irinotecan (CPT-11), Clin. Cancer Res., 7, 2182
  146. Swami, 2013, Therapeutic targeting of CPT-11 induced diarrhea: a case for prophylaxis, Curr. Drug Targets, 14, 777, 10.2174/1389450111314070007 · DOI
  147. Chiocca, 2011, Phase IB study of gene-mediated cytotoxic immunotherapy adjuvant to up-front surgery and intensive timing radiation for malignant glioma, J. Clin. Oncol., 29, 3611, 10.1200/JCO.2011.35.5222 · DOI · Paper page
  148. Finocchiaro, 2012, Cytokine-enhanced vaccine and suicide gene therapy as surgery adjuvant treatments for spontaneous canine melanoma: 9years of follow-up, Cancer Gene Ther., 19, 852, 10.1038/cgt.2012.72 · doi:10.1038/cgt.2012.72
  149. Xiong, 2012, Novel, chimeric, cancer-specific, and radiation-inducible gene promoters for suicide gene therapy of cancer, Cancer, 118, 536, 10.1002/cncr.26289 · DOI
  150. Liao, 2009, Radiation enhances suicide gene therapy in radioresistant laryngeal squamous cell carcinoma via activation of a tumor-specific promoter, Cancer Lett., 283, 20, 10.1016/j.canlet.2009.03.021 · doi:10.1016/j.canlet.2009.03.021
  151. Louis, 2011, Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma, Blood, 118, 6050, 10.1182/blood-2011-05-354449 · DOI · Paper page
  152. Kalos, 2011, T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia, Sci. Transl. Med., 3, 95ra73, 10.1126/scitranslmed.3002842 · DOI · Paper page
  153. Zhong, 2010, Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8+ T cell-mediated tumor eradication, Mol. Ther., 18, 413, 10.1038/mt.2009.210 · DOI · Paper page
  154. Tey, 2014, Adoptive T-cell therapy: adverse events and safety switches, Clin. Transl. Immunol., 3, e17, 10.1038/cti.2014.11 · DOI
  155. Mailly, 2010, Genetically engineered T-cells expressing a ganciclovir-sensitive HSV-tk suicide gene for the prevention of GvHD, Curr. Opin. Investig. Drugs, 11, 559
  156. Faneca, 2008, Synergistic antitumoral effect of vinblastine and HSV-Tk/GCV gene therapy mediated by albumin-associated cationic liposomes, J. Control. Release, 126, 175, 10.1016/j.jconrel.2007.12.005 · DOI
  157. Boucher, 2005, In vitro and in vivo enhancement of ganciclovir-mediated bystander cytotoxicity with gemcitabine, Mol. Ther., 12, 1064, 10.1016/j.ymthe.2005.07.643 · doi:10.1016/j.ymthe.2005.07.643
  158. Zhang, 2012, Multifunctional nanomedicine platforms for cancer therapy, J. Nanosci. Nanotechnol., 12, 4012, 10.1166/jnn.2012.6160 · doi:10.1166/jnn.2012.6160
  159. Duarte, 2012, Suicide gene therapy in cancer: where do we stand now?, Cancer Lett., 324, 160, 10.1016/j.canlet.2012.05.023 · DOI · Paper page
  160. Kurayoshi, 2014, Cancer cell specific cytotoxic gene expression mediated by ARF tumor suppressor promoter constructs, Biochem. Biophys. Res. Commun., 450, 240, 10.1016/j.bbrc.2014.05.102 · doi:10.1016/j.bbrc.2014.05.102
  161. Leja, 2007, A novel chromogranin — a promoter-driven oncolytic adenovirus for midgut carcinoid therapy, Clin. Cancer Res., 13, 2455, 10.1158/1078-0432.CCR-06-2532 · doi:10.1158/1078-0432.ccr-06-2532
  162. Kia, 2012, Dual systemic tumor targeting with ligand-directed phage and Grp78 promoter induces tumor regression, Mol. Cancer Ther., 11, 2566, 10.1158/1535-7163.MCT-12-0587 · DOI
  163. Haviv, 2004, Transcriptional targeting in renal cancer cell lines via the human CXCR4 promoter, Mol. Cancer Ther., 3, 687, 10.1158/1535-7163.687.3.6 · DOI
  164. Zhu, 2004, Transcriptional targeting of adenoviral vector through the CXCR4 tumor-specific promoter, Gene Ther., 11, 645, 10.1038/sj.gt.3302089 · DOI
  165. Rajendran, 2013, Adenovirus-mediated transcriptional targeting of colorectal cancer and effects on treatment-resistant hypoxic cells, Clin. Colorectal Cancer, 12, 152
  166. Balani, 2009, High mobility group box2 promoter-controlled suicide gene expression enables targeted glioblastoma treatment, Mol. Ther., 17, 1003, 10.1038/mt.2009.22 · DOI
  167. Akerstrom, 2013, Adenoviral insulinoma-associated protein 1 promoter-driven suicide gene therapy with enhanced selectivity for treatment of neuroendocrine cancers, Ochsner J., 13, 91
  168. Tsuruta, 2008, A fiber-modified mesothelin promoter-based conditionally replicating adenovirus for treatment of ovarian cancer, Clin. Cancer Res., 14, 3582, 10.1158/1078-0432.CCR-07-5053 · doi:10.1158/1078-0432.ccr-07-5053
  169. Hine, 2012, Rad51 promoter-targeted gene therapy is effective for in vivo visualization and treatment of cancer, Mol. Ther., 20, 347, 10.1038/mt.2011.215 · doi:10.1038/mt.2011.215
  170. Hine, 2008, Use of the Rad51 promoter for targeted anti-cancer therapy, Proc. Natl. Acad. Sci. U. S. A., 105, 20810, 10.1073/pnas.0807990106 · DOI
  171. Fontecedro, 2010, Analysis of adenovirus trans-complementation-mediated gene expression controlled by melanoma-specific TETP promoter in vitro, Virol. J., 7, 175, 10.1186/1743-422X-7-175 · DOI

Cited by

See all 192

Metadata

Authors
Karjoo, Z., Chen, X., & Hatefi, A.
Venue
Advanced Drug Delivery Reviews
Publisher
Elsevier BV
Published
2016-04
Volume
99
Issue
Pt A
Pages
113-128
ISSN
0169-409X (ISSN-L)
OpenAlex
W209377287
Cited by
192
References
2
FWCI
1.84
Type
journal article
Language
en
Open access
bronze
Funders
  • Department of Defense (PC081055)
  • National Cancer Institute (R01CA175318)
  • National Institute of Biomedical Imaging and Bioengineering (R21EB016792)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Progress and problems with the use of suicide genes for targeted cancer therapy. https://app.cochat.ai/papers/10.1016/j.addr.2015.05.009
The paper
Karjoo, Z., Chen, X., & Hatefi, A. (2016). Progress and problems with the use of suicide genes for targeted cancer therapy. Advanced Drug Delivery Reviews. https://doi.org/10.1016/j.addr.2015.05.009

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.